483 Roundup: FDA Hits Facilities for Inadequate CAPAs, Investigations

The GMP Letter
A A
The FDA flagged three U.S. facilities and two in Europe for a variety of deficiencies including CAPA failures and investigations of nonconforming products.

To View This Article:

Login

Subscribe To The GMP Letter